SIP
MDCO

Stoneridge Investment Partners’s Medicines Co MDCO Stock Holding History

Stoneridge Investment Partners’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,603
Closed -$679K – 211
2018
Q1 		$679K Sell
20,603
-6,398
-24% -$200K 0.11% 101
2017
Q4 		$738K Buy
27,001
+1,650
+7% +$50.8K 0.12% 103
2017
Q3 		$939K Sell
25,351
-3,785
-13% -$140K 0.15% 109
2017
Q2 		$1.11M Buy
+29,136
New +$1.3M 0.16% 110

Other funds holding MDCO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Stoneridge Investment Partners's MDCO Position: Q2 2018 in Review

Stoneridge Investment Partners sold out of Medicines Co (MDCO) in Q2 2018, closing a stake of 20,603 shares — an estimated $679K sold.

Stoneridge Investment Partners first reported a position in MDCO in Q2 2017 and held it in 4 quarters. The position peaked at $1.11M in Q2 2017. 188 funds tracked by Wall St. Rank hold MDCO as of Q2 2018.

  • Stoneridge Investment Partners reported no remaining Medicines Co position as of Q2 2018 after selling out during the quarter.
  • Stoneridge Investment Partners sold 20,603 Medicines Co shares in Q2 2018, an estimated $679K.
  • Stoneridge Investment Partners first reported a position in Medicines Co in Q2 2017 and held it in 4 quarters.
  • Stoneridge Investment Partners's Medicines Co position peaked at $1.11M in Q2 2017.
  • 188 funds tracked by Wall St. Rank held Medicines Co as of Q2 2018.

Based on Stoneridge Investment Partners's 13F filing for Q2 2018, filed 31 Jul 2018.